311 related articles for article (PubMed ID: 23094715)
1. Current pharmacotherapy for cholestatic liver disease.
Carey EJ; Lindor KD
Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
[TBL] [Abstract][Full Text] [Related]
2. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
4. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
5. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
7. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
8. Therapy with ursodeoxycholic acid in cholestatic liver disease.
Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
Stiehl A
Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
[TBL] [Abstract][Full Text] [Related]
10. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
11. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
12. [Cholestasis: therapeutic options].
Beuers U; Oswald M
Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid for the treatment of cholestatic diseases.
Poupon RE; Poupon R
Prog Liver Dis; 1992; 10():219-38. PubMed ID: 1296231
[No Abstract] [Full Text] [Related]
15. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
16. Management of autoimmune and cholestatic liver disorders.
Krok KL; Munoz SJ
Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
[TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of cholestatic hepatopathies].
Leuschner U
Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
[TBL] [Abstract][Full Text] [Related]
18. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of autoimmune biliary diseases.
Imam MH; Talwalkar JA; Lindor KD
J Autoimmun; 2013 Oct; 46():88-96. PubMed ID: 23860242
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
